Literature DB >> 27407795

Tamoxifen Therapy for Breast Cancer and Endometrial Pathology.

Sps Kochar1, P Arora2, A B Chattopadhyay3.   

Abstract

BACKGROUND: Tamoxifen, used as adjuvant therapy for carcinoma breast in postmenopausal women to prevent relapse has estrogenic effect on the endometrium.
METHODS: 104 patients on tamoxifen for more than six months were subjected to a clinical examination and transvaginal sonography. Patients with endometrial thickness > 8 mm were further evaluated by hysteroscopy and endometrial biopsy.
RESULTS: 35(34%) patients were symptomatic. The average endometrial thickness was 11.2 mm which correlated with duration of tamoxifen use. 27(48%) patients had abnormal hysteroscopic findings. 35 (63%) of endometrial biopsies revealed abnormal endometrium. One case of endometrial carcinoma was diagnosed. The results were statistically analysed. There is a significant association between symptomatic status and endometrial thickness and duration of tamoxifen use.
CONCLUSION: All patients on long term tamoxifen should be annually screened for endometrial pathology.

Entities:  

Keywords:  Endometrium; Tamoxifen; Transvaginal sonography

Year:  2011        PMID: 27407795      PMCID: PMC4922966          DOI: 10.1016/S0377-1237(05)80052-8

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  9 in total

Review 1.  Overview of studies on endometrial cancer and other types of cancer in humans: perspectives of an epidemiologist.

Authors:  B MacMahon
Journal:  Semin Oncol       Date:  1997-02       Impact factor: 4.929

Review 2.  Tamoxifen and endometrial pathologies: a prospective study.

Authors:  M Seoud; A Shamseddine; A Khalil; Z Salem; N Saghir; K Bikhazi; N Bitar; G Azar; H Kaspar
Journal:  Gynecol Oncol       Date:  1999-10       Impact factor: 5.482

3.  The incidence of subsequent endometrial carcinoma with tamoxifen use in patients with primary breast carcinoma.

Authors:  K Katase; Y Sugiyama; K Hasumi; M Yoshimoto; F Kasumi
Journal:  Cancer       Date:  1998-05-01       Impact factor: 6.860

4.  Endometrial pathology of 104 postmenopausal breast cancer patients treated with tamoxifen.

Authors:  S Ozşener; A Ozaran; I Itil; Y Dikmen
Journal:  Eur J Gynaecol Oncol       Date:  1998       Impact factor: 0.196

5.  Association between endometrial cancer and tamoxifen treatment of breast cancer.

Authors:  C Peters-Engl; W Frank; E Danmayr; H P Friedl; S Leodolter; M Medl
Journal:  Breast Cancer Res Treat       Date:  1999-04       Impact factor: 4.872

6.  Endometrial thickness in tamoxifen-treated patients: correlation with clinical and pathologic findings.

Authors:  L E Hann; C S Giess; A M Bach; Y Tao; H J Baum; R R Barakat
Journal:  AJR Am J Roentgenol       Date:  1997-03       Impact factor: 3.959

7.  Endometrial pathology in postmenopausal tamoxifen treatment: comparison between gynaecologically symptomatic and asymptomatic breast cancer patients.

Authors:  I Cohen; E Perel; D Flex; R Tepper; M M Altaras; M Cordoba; Y Beyth
Journal:  J Clin Pathol       Date:  1999-04       Impact factor: 3.411

Review 8.  Surveillance for endometrial cancer in women receiving tamoxifen.

Authors:  E J Suh-Burgmann; A Goodman
Journal:  Ann Intern Med       Date:  1999-07-20       Impact factor: 25.391

9.  Tamoxifen therapy for breast cancer and endometrial cancer risk.

Authors:  L Bernstein; D Deapen; J R Cerhan; S M Schwartz; J Liff; E McGann-Maloney; J A Perlman; L Ford
Journal:  J Natl Cancer Inst       Date:  1999-10-06       Impact factor: 13.506

  9 in total
  2 in total

1.  Uterine changes during tamoxifen, toremifene, and other therapy for breast cancer: evaluation with magnetic resonance imaging.

Authors:  Junko Ochi; Katsumi Hayakawa; Yoshio Moriguchi; Yoji Urata; Akira Yamamoto; Kanae Kawai
Journal:  Jpn J Radiol       Date:  2010-07-27       Impact factor: 2.374

2.  Endometrial evaluation by ultrasonography, hysteroscopy and histopathology in cases of breast carcinoma on Tamoxifen therapy.

Authors:  Alka Jindal; Manjit K Mohi; Manjeet Kaur; Balwinder Kaur; Risham Singla; Shaunik Singh
Journal:  J Midlife Health       Date:  2015 Apr-Jun
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.